Pulmonary Embolism
Conditions
Keywords
Pulmonary Embolism, Venous Thromboembolism, Chronic Thromboembolic Disease
Brief summary
Acute Pulmonary Embolism (PE) is the most serious clinical presentation of venous thromboembolism (VTE), a leading cause of cardiovascular mortality, exceeded only by stroke and myocardial infarction. Chronic thromboembolic pulmonary hypertension (CTEPH) is the most severe chronic form of CTED and it occurs in 2-4% of patients after acute PE. In Portugal little is known about PE epidemiology and its outcomes, including complications like CTED. The main goal of this study is, therefore, to understand PE epidemiology and complications in the northern region of Portugal. This information can enable the organization of a structured health care network that can potentially benefit all PE patients.
Interventions
None listed
Sponsors
Unidade Local de Saúde de Matosinhos, EPE
Centro Hospitalar Universitário do Porto
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Hospital da Luz, Portugal
Hospital Centre Hospitalar de Trás-os-Montes e Alto Douro
Hospital de Braga
Centro Hospitalar de Entre o Douro e Vouga
Unidade Local de Saúde do Alto Minho
Universidade do Porto
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Acute symptomatic or asymptomatic PE, * Age \>18 years, * Availability of a minimum data set for PE and a minimum of 3-months follow-up for the primary objective and 36-months for the secondary one. Except for patients who died prior to the 3 or 36 months follow-up.
Exclusion criteria
* Enrolment of the patient in any treatment trial in a blinded fashion, * Lack or withdrawal of patient´s consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine Pulmonary Embolism (PE) prevalence in Portugal | From date of inclusion until the end of the study currently planned (3 to 5 years) | Number cases per year |
| Identification of Pulmonary Embolism (PE) risk factors and comorbidities | From date of inclusion until the end of the study currently planned (3 to 5 years) | Frequency of risk factors and comorbidities |
| Determine Pulmonary Embolism (PE) clinical management. | From date of inclusion until the end of the study currently planned (3 to 5 years) | Identification of diagnostic of diagnostic and treatment profile |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Access incidence rate of Chronic Thromboembolic Disease (CTED) with or without pulmonary hypertension after acute PE. | From 6 months after date of inclusion until the end of the study currently planned (2 to 5 years) | ratio between the number of patients with CTED with or without pulmonary hypertension and total number of patients with PE |
Contacts
Primary ContactCarolina Guedes, MD, PhDc
Backup ContactJanete Santos, PhD
Outcome results
None listed